Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Boehringer Ingelheim | INDUSTRY |
| Grupo Argentino de Investigación Clínica en Oncología | UNKNOWN |
| Grupo de Estudios Clínicos Oncológicos Peruano | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Currently, there is a hypothesis that there is not enough evidence to fully understand the patient journey and accurately determine the clinical outcomes of neuroendocrine carcinomas (NEC) in Latin America. A better understanding of this landscape, including its unique regional aspects, could lead to improved patient care.
To address this gap, this observational, retrospective, non-interventional study aims to describe treatment patterns and outcomes for patients with both pulmonary and extra-pulmonary NEC in Latin America. Eligible patients diagnosed with either form of NEC will be included, and data will be collected from medical records at selected sites across Brazil, Mexico, Argentina, and Peru.
Data to be retrieved include but are not limited to age at diagnosis, gender, ECOG at diagnosis, stage (TNM), resources used for primary diagnosis (imaging, upfront surgery etc.), primary site, tumor size and grade, setting of initial treatment (reference center vs community hospital), type of initial surgical approach, data of anti-cancer treatments (including (neo)adjuvant and advanced settings) and relapse and/or progression/death. Data regarding anti-cancer treatments (including (neo)adjuvant and advanced settings), as well as radiotherapy use will also be recorded.
As this project is non-interventional, patients will still receive treatment and clinical assessments for extra-pulmonary and pulmonary NEC as determined by their attending physician, according to the standard of care and routine clinical practice at each site. No visits are demanded by the study, but for those required for the consent process whenever determined by the local ethics committee. Patient source data will be taken from the patient's medical records and reported by means of an electronic data capture (EDC) system.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with extra-pulmonary neuroendocrine carcinoma | Patients with Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), diagnosed between August 2014 and August 2024. |
| |
| Patients with pulmonary neuroendocrine carcinoma | Patients with Large-cell neuroendocrine carcinoma (LCNEC) or mixed and patients with Small Cell Lung Cancer (SCLC) or mixed, diagnosed between August 2014 and August 2024. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Observational study | Other | This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Patterns of Initial Cancer Treatment: number of participants treated within vs. outside high-volume sites and associated treatment characteristics | Treatment patterns will be analyzed descriptively using tables and graphs to illustrate the distribution of patients receiving initial cancer treatment within versus outside high-volume treatment centers. Key characteristics of the initial treatment will be assessed. | Throughout the study period, an average of 24 months |
| Event-free survival (EFS) | defined as time from diagnosis until relapse, death, or definitive failure of treatment strategy that implicates failure of curative-intent treatment [for patients treated with curative intent]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact. | Throughout the study period, an average of 24 months |
| Time to treatment failure (TTF) | in first and second-line: defined as time from first dose of treatments until date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death. Participants who are lost to follow up or reach the study end will be censored at their last date of contact | Throughout the study period, an average of 24 months |
| Progression-free survival (PFS) | defined as time from treatment initiation until progression or death [for patients treated with palliative intent]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact. | Throughout the study period, an average of 24 months |
| Overall survival | [according to disease stage/setting], defined as time from initial diagnosis until date of death from any cause. Participants who are lost to follow up or reach the study end will be censored at their last date of contact. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with extra-pulmonary neuroendocrine carcinoma (EP-NEC) and patients with pulmonary neuroendocrine carcinoma (SCLC or LCNEC) from Brazil, Mexico, Argentina and Peru.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Project Manager | Contact | +55 51 3384 5334 | lacog1324@lacog.group | |
| Laura Voelcker | Contact | +55 51 3384 5334 | laura.voelcker@lacog.group |
| Name | Affiliation | Role |
|---|---|---|
| Rachel Simões Pimenta Riechelmann | Latin American Cooperative Oncology Group | Principal Investigator |
| Vladmir Cláudio Cordeiro de Lima | Latin American Cooperative Oncology Group | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D018278 | Carcinoma, Neuroendocrine |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D019370 | Observation |
| ID | Term |
|---|---|
| D008722 | Methods |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Tumor block: Formalin-Fixed Paraffin-Embedded collected from 2014 onwards.
| Throughout the study period, an average of 24 months |
| Frequency of DLL-3 immunohistochemistry expression | Rate of patients with DLL3 expression in extra-pulmonary and pulmonary NEC by IHC [stratified by tumor primary site] | After the end of recruitment, an average of 1 year |
| D009369 | Neoplasms |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |